Remote delivery and expression of soluble type II TGF-β receptor in muscle prevents hepatic fibrosis in rats

被引:10
作者
Nakamuta, M [1 ]
Morizono, S [1 ]
Tsuruta, S [1 ]
Kohjima, M [1 ]
Kotoh, K [1 ]
Enjoji, M [1 ]
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Higashi Ku, Fukuoka 8128582, Japan
关键词
soluble TGF-beta receptor; type I collagen; Th1/Th2; cytokines; biofactory; intramuscular injection;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Transforming growth factor-beta (TGF-beta) has been implicated in the process of hepatic fibrosis, and stimulates production of extracellular matrix in hepatic stellate cells, which play a major role in the process. It has been recently reported that blockage of TGF-beta signaling prevents hepatic fibrosis. We evaluated a strategy for anti-TGF-beta gene therapy for hepatic fibrosis by transfecting plasmids expressing an entire extracellular domain of human TGF-beta type II [soluble type II TGF-beta receptor (sTGF-beta IIR)] into skeletal muscle in a rat experimental model of dimethylnitrosamine- (DMN-) induced fibrosis. sTGF-beta IIR treatment decreased significantly the occurrence of DMN-induced hepatic fibrosis, evaluated by computed image analysis and by measurement of hydroxyproline content of the liver, and reduced the expression of collagen and a-smooth muscle actin. The treatment also caused a significant decrease in hepatic levels of interleukin- (IL-) 12 (Th1 cytokine) and an increase in those of IL-10 (Th2 cytokine), indicating a change in the Th1/Th2 cytokine balance in the liver. In conclusion, blockade of TGF-beta after intramuscular transfer of the soluble type II TGF-beta receptor gene suppressed hepatic fibrosis, suggesting that this strategy may be useful for gene therapy of hepatic fibrosis.
引用
收藏
页码:59 / 64
页数:6
相关论文
共 45 条
  • [1] FORMATION OF EXTRACELLULAR-MATRIX IN NORMAL RAT-LIVER - LIPOCYTES AS A MAJOR SOURCE OF PROTEOGLYCAN
    ARENSON, DM
    FRIEDMAN, SL
    BISSELL, DM
    [J]. GASTROENTEROLOGY, 1988, 95 (02) : 441 - 447
  • [2] BEDOSSA P, 1995, J HEPATOL, V22, P37
  • [3] BORDER WA, 1994, NEW ENGL J MED, V331, P1286
  • [4] TGF-β and fibrosis
    Branton, MH
    Kopp, JB
    [J]. MICROBES AND INFECTION, 1999, 1 (15) : 1349 - 1365
  • [5] The antioxidant (-)-epigallocatechin-3-gallate inhibits activated hepatic stellate cell growth and suppresses acetaldehyde-induced gene expression
    Chen, AP
    Zhang, L
    Xu, JY
    Tang, J
    [J]. BIOCHEMICAL JOURNAL, 2002, 368 (03) : 695 - 704
  • [6] Inhibitory effect of a soluble transforming growth factor β type II receptor on the activation of rat hepatic stellate cells in primary culture
    Cui, XZ
    Shimizu, I
    Lu, GM
    Itonaga, M
    Inoue, H
    Shono, M
    Tamaki, K
    Fukuno, H
    Ueno, H
    Ito, S
    [J]. JOURNAL OF HEPATOLOGY, 2003, 39 (05) : 731 - 737
  • [7] FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828
  • [8] HEPATIC LIPOCYTES - THE PRINCIPAL COLLAGEN-PRODUCING CELLS OF NORMAL RAT-LIVER
    FRIEDMAN, SL
    ROLL, FJ
    BOYLES, J
    BISSELL, DM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (24) : 8681 - 8685
  • [9] Transforming growth factor β1 induces the expression of α1(I) procollagen mRNA by a hydrogen peroxide-C/EBPβ-dependent mechanism in rat hepatic stellate cells
    García-Trevijano, ER
    Iraburu, MJ
    Fontana, L
    Domínguez-Rosales, JA
    Auster, A
    Covarrubias-Pinedo, A
    Rojkind, M
    [J]. HEPATOLOGY, 1999, 29 (03) : 960 - 970
  • [10] In vivo inhibition of rat stellate cell activation by soluble transforming growth factor β type II receptor:: A potential new therapy for hepatic fibrosis
    George, J
    Roulot, D
    Koteliansky, VE
    Bissell, DM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (22) : 12719 - 12724